ArticleNeuroscience journal2013
Surgical Outcome of Treating Grades II and III Meningiomas: A Report of 32 Cases.
Article in Neuroscience journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Volumetric growth rates of meningioma and its correlation with histological diagnosis and clinical outcome: a systematic review.Acta neurochirurgica · 2017Pooled it
- Malignant Transformation of Meningiomas.Journal of Cancer · 2025Review
- Predictors of Postoperative Epilepsy/Seizures in Patients Readmitted After Meningioma Resection.Behavioural neurology · 2025Article
- Automated volumetry of meningiomas in contrast-enhanced T1-Weighted MRI using deep learning.World neurosurgery: X · 2024Article
- Surgical strategies for intracranial meningioma in the molecular era.Journal of neuro-oncology · 2023Review
- Clear cell histology portends a worse prognosis than other WHO grade II histologies.Journal of neuro-oncology · 2021Article
- Basis for Immunotherapy for Treatment of Meningiomas.Frontiers in neurology · 2020Review
- Meningioma recurrence rates following treatment: a systematic analysis.Journal of neuro-oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim. To evaluate the frequency of atypical and malignant meningiomas and analyze recurrence rate; to study the morbidity and mortality of these tumors compared to benign meningiomas. Methods. During 1992-2007, 16 patients with malignant and 16 patients with atypical meningioma were operated in Neurosurgery Department of Thessaloniki's Papanikolaou Hospital. We analyzed tumor histology, location, and extent of surgical resection with respect to tumor reappearance and patients' outcome and compared the behavior of benign versus nonbenign meningiomas. Results. Malignant meningiomas accounted for 4.4% (16 patients) and atypical meningiomas for another 4.4% of the series of patients (353) who were operated for intracranial meningioma at our department that period. Malignant meningiomas recurred at a rate of 75% and atypical meningiomas recurred at a rate of 41.6%. There was a significant association of the histological classification (benign, atypical, and malignant) with recurrence (P < 0.01). The recurrence rate after complete resection was 13.8%. The recurrence rate for incomplete resection was 46.7%. Extent of tumor removal was significant to recurrence (P < 0.001) for benign as well for atypical and malignant meningiomas. Tumor location (P > 0.05) was not significant to recurrence. Conclusions. Atypical and malignant meningiomas appeared at a rate of 8.8% of our series of intracranial meningiomas. They showed a significant predisposition to recur. These rare subtypes have higher morbidity and mortality rates than benign meningiomas. Recurrence depends primarily on the extent of surgical removal and on the histological characterization of the tumor as atypical or malignant.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.